ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Valencia, VC, ESP:

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing multiple my ...

Enrolling
Smoldering Multiple Myeloma (SMM)
Drug: Linvoseltamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, Spain and 14 other locations

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 48 other locations

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Dexamethasone
Drug: Melphalan

Phase 2

PETHEMA Foundation

Valencia, Spain and 15 other locations

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...

Enrolling
High-Risk de Novo Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

PETHEMA Foundation

Valencia, Spain and 9 other locations

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Valencia, Spain and 126 other locations

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer
Pfizer

Valencia, Spain and 78 other locations

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: CC-93269

Phase 1

Celgene
Celgene

Valencia, Spain and 34 other locations

Locations recently updated

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

València, Spain and 238 other locations

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 53 other locations

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...

Enrolling
Multiple Myeloma
Drug: Linvoseltamab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, València, Spain and 21 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems